



Peri-procedural Management Summary Chart

ren-procedurat managemen						
Procedure	Category		BMP			Suggestions
Ablation Procedure - Liver	2	x		x	x	Unasyn 1.5-3g IV, Ceftriaxone 1g, Vancomycin 1g
Ablation Procedure - Renal Ablation Procedure - Bone	3	x	x	x	x	Ceftriaxone 1g, Unasyn 1.5-3g IV
Abscess Drainage	2	x	<u> </u>	x	x	Cefazolin 2g, Clindamycin 600mg Ceftriaxone 1g, Ampicillin-sulbactam 3g IV, Cefotetan 1-2g IV
Angiogram - Diagnostic	2	x	x	x	x	Cefazolin 2g, Clindamycin 600mg
Angiogram - Therapeutic with Bland Embolization - Trauma	2	x	x	x	x	Cefazolin 2g + Metronidazole 500mg, Clindamycin 600mg + Gentamicin 1.5 mg/kg
Angiogram - Therapeutic with Bland Embolization - UAE	2	x	x	x	x	Cefazolin 2g, Clindamycin 600mg + Gentamicin 1.5 mg/kg
Angiogram - Therapeutic with Bland Embolization - GI Bleed	2	x	x	x	x	Cefazolin 2g, Clindamycin 600mg
Angiogram - Hepatic Chemoembolization and SIRT routine	2	x	x	x	x	Cefazolin 2g + Metronidazole 500mg, Ampicillin-sulbactam 3g, see chart
Angiogram - Hepatic Chemoembolization and SIRT complex	2	x	x	х	x	Moxifloxicin 400mg PO starting 3 days prior to the procedure and continuing for 17 days post
Angiogram - Pulmonary	2	x	x	x		
Biliary Tube - Initial Insertion	3	x	x	x	x	Zosyn 3.375g, Ceftriaxone 1g, Unasyn 1.5-3, Clindamycin 600mg IV + Gentamicin 1.5mg/kg
Biliary Tube - Check (tube injection)	1				x	Zosyn 3.375g, Ceftriaxone 1g, Unasyn 1.5-3, Clindamycin 600mg IV + Gentamicin 1.5mg/kg
Biliary Tube - Exchange	1	x	x	x	x	Zosyn 3.375g, Ceftriaxone 1g, Unasyn 1.5-3, Clindamycin 600mg IV + Gentamicin 1.5mg/kg
Biopsy - Superficial (thyroid, lymph node)	1					
Biopsy - Deep (liver, lung, retroperitoneal)	2	x		x		
Biopsy - Bone	2	x		x		
Biopsy - High Risk (Renal)	3	x	<u> </u>	x		Cieve 500me DO BID fex 3 deve start dev eview to biosevi
Biopsy - Transrectal Biopsy - Transjugular Liver Biopsy	2	x	<u> </u>	x	x	Cipro 500mg PO BID for 3 days start day prior to biopsy
Breast Biopsy - core or vacuum biopsy	1	^	-	^		
Choleystostomy Tube - Placement	2	x		x	x	Zosyn 3.375g, Ceftriaxone 1g, Unasyn 1.5-3, Clindamycin 600mg IV + Gentamicin 1.5mg/kg
Choleystostomy Tube - Exchange	1	x		x	x	Zosyn 3.375g, Ceftriaxone 1g, Unasyn 1.5-3, Clindamycin 600mg IV + Gentamicin 1.5mg/kg
Denver Shunt Placement	2	x	x	x	x	Ceftriaxone 1g, Levaquin 500mg, consider continuing 5-7 days
Dialysis - Fistulogram/Graftogram with treatment	1				x	Ancef 2g IV, Clindamycin 600mg IV
Dialysis - Declot (Thrombectomy or Thrombolysis)	1				x	Ancef 2g IV, Clindamycin 600mg IV
Dialysis - Tunnelled Catheter Placement/conversion to tunneled		x		x	x	Ancef 2g IV, Clindamycin 600mg IV
Dialysis - Tunnelled Catheter Exchange	2	x		x	x	Ancef 2g IV, Clindamycin 600mg IV
Dialysis - Temporary Catheter Insertion	1	x		x		
Dialysis - Temporary Catheter Exchange	1					
Dialysis - Temporary Catheter Removal	1	x		x		
Fiducial Marker Placement	2	x		x	x	Cefazolin 2g, Clindamycin 600mg, site dependant
Foreign Body Retrieval	2	x		x		
G or J Tube - Initial Placement push technique	2	x		х		
G or J Tube - Initial Placement pull technique	2	x		х	x	Ancef 1-2g, Vancomycin 1g, clindamycin 600mg, cefoxitin 1-2g
G or J Tube - Exchange or Re-Insertion	1					Ancef 1-2g, Vancomycin 1g, clindamycin 600mg, cefoxitin 1-2g
IVC Filter Placement or Removal	1	x	x	x		
Kyphoplasty	2	x	x*	x	x	Ancef 2g IV, Clindamycin 600mg IV
Lumbar Puncture and Myelogram	2					
Musculoskeletal procedure - arthrogram, aspiration, etc	1					
Nephrostomy Tube - Placement	3	x	x	x	x	Cefazolin 2g IV, Ceftriaxone 1g IV, Ampicillin-sulbactam 3g IV, Clindamycin 600mg IV + Gentamicin 1.5m
Nephrostomy Tube - Nephrostogram or Removal Nephrostomy Tube - Routine Exchange	1	~	<u> </u>	x	~	No antibiotic necessary unless concern fore infection then as per insertion
Nephrostomy Tube - Complex exchange, possible re-access	1/2	x	<u> </u>	x	x	Cefazolin 2g IV, Ceftriaxone 1g IV, Ampicillin-sulbactam 3g IV, Clindamycin 600mg IV + Gentamicin 1.5r
Nephro-Ureteral Stent - Placement	2	x	<u> </u>	x	x	Cefazolin 2g IV, Ceftriaxone 1g IV, Ampicillin-subactam 3g IV, Clindamycin 600mg IV + Gentamicin 1.5r
Nephro-Ureteral Stent - Routine Exchange	1	x	-	x	x	No antibiotic necessary unless concern than as per insertion
Nephro-Ureteral Stent - Complex Exchange, possible re-access	1/2	x		x	x	Cefazolin 2g IV, Ceftriaxone 1g IV, Ampicillin-sulbactam 3g IV, Clindamycin 600mg IV + Gentamicin 1.5m
Nephro-Ureteral Stent - Study	1				~	
Paracentesis	1					
Pleurex Catheter Placement	2	x			x	Ancef 2g IV, Clindamycin 600mg IV
PICC line Insertion	1					
Port - Placement	2	x		x	x	Ancef 2g IV, Clindamycin 600mg IV
Port - Removal	2	x		х		
Port Check and Catheter Injection	1					
Supra Pubic Tube - Placement	2	х		x	x	Cefazolin 2g IV, Ceftriaxone 1g IV, Ampicillin-sulbactam 3g IV, Clindamycin 600mg IV + Gentamicin 1.5
Supra Pubic Tube - Exchange	1					No antibiotic necessary unless concern then as per insertion
Tenkoffogram - possible manipulation	2	x		х	x	Cefazolin 2g, Clindamycin 600mg
Thoracentesis	1	x		x		
TIPS Transjugular intrahepatic portosytemic shunt	3	x	x	x	x	Ceftriaxone 1g, Unasyn 1.5-3, Clindamycin 600mg IV + Gentamicin 1.5mg/kg
Uterine Artery Embolization	2	x	x	x	x	cefazolin 2g IV, Clindamycin 600mg IV + Gentamicin 1.5mg/kg, Unasyn 1.5-3g IV,
Uterine Artery Embolization with hydrosalpinx	2	x	x	x	x	Above + Doxycycline 100mg PO x 7 days
Venogram - mapping study	1				-	Colonalla Da Cilada annala (Obara
Venous Embolization	1	X	X	x	×	Cefazolin 2g, Clindamycin 600mg
	1	x	x	x		Cefazolin 2g, Clindamycin 600mg
Venogram - lower extremity						
Coags = PT, INR, PTT	ing questio	pnaire	for co	agula	nathy	
Coags = PT, INR, PTT ***Any case NOT requiring coags/CBC must have negative screen						to procedure
Coags = PT, INR, PTT ***Any case NOT requiring coags/CBC must have negative screen ***Any patient with known or suspected liver disease or taking c	oumadin sh					to procedure
Coags = PT, INR, PTT ***Any case NOT requiring coags/CBC must have negative screen ***Any case NOT requiring coags/CBC must have negative screen ***Any patient with known or suspected liver disease or taking c ***Any patient on heparin should undergo PTT or ACT prior to pr	oumadin sh ocedure	ould un	dergo			to procedure
Coags = PT, INR, PTT ***Any case NOT requiring coags/CBC must have negative screen ***Any patient with known or suspected liver disease or taking c	oumadin sh ocedure	ould un	dergo			to procedure

Pre-Procedure and Peri-Procedural Anticoagulation Management (10-30-17)




Peri-Procedural Management of Anticoagulation and Antiplatelet Agents

The Following chart summarizes general guidelines for management of anti-platelet and anti-coagulant medications prior to a planned procedure. It should be pointed out that these summarize general guidelines and that each patient needs to be considered on an individual basis and all clinical factors and risk factors need to be considered in light of these more general guidelines. Peri-procedural



management of medications are ultimately at the discretion of the physician performing the proposed



procedure.



Procedure	INR	Platelets	ASA	Anti- Platelet	Anticoag
 Category 1 Procedures - Procedures with Low Risk of Bleeding Vascular Procedures Venous interventions (note if DVT than see exclusions) Central Line Removal IVC Filter Placement Tunneled catheter placement Non-Vascular Procedures Superficial biopsy (thyroid,etc.) Non-tunneled catheter Tunneled catheter removal Paracentesis Drainage tube exchange (nephrostomy, biliary, abscess) Superficial abscess/cyst drainage Joint Aspiration - for needles ≥ 18 gauge 	≤ 2.0	≥ 50,000	Do not withhold	Withhold 5 days	Possibly Withhold
 Breast Biopsy with 14 g core or 9 g vacuum device or FNA 	≤ 2.0	≥ 50,000	Withhol d 5 days	Withhold 5 days	Possibly Withhold



 <u>Category 2</u> - Procedures with Moderate Risk of Bleeding <u>Vascular Procedures</u> Angiography - all types Trans-jugular liver biopsy Port placement and removal <u>Non-vascular procedures</u> Deep drainages Deep Biopsies (liver, retroperitoneal, lung, etc.) Cholecystostomy Vertebral Augmentation Lumbar Puncture and myelogram Percutaneous ablation Gastrostomy tube placement 	≤ 1.5	≥ 50,000	Withhol d 5 days	Withhold 5 days	Possibly Withhold
Category 3 - Procedures with Significant Risk of Bleeding Vascular Procedures • TIPS Non-vascular procedures • Renal biopsy • Biliary drainages/intervention • Nephrostomy tube placement	≤ 1.5	≥ 50,000	Withhol d 5 days	Withhold 5 days	Possibly Withhold

	VASCULAR
AMI	INSTITUTE

 Exclusions and Possible Exclusions (Pre-procedure coagulation testing not required) Dialysis graft/fistulogram IVC Filter Removal and on anticoagulation PICC Placement Peripheral venography Venous interventions in the setting of DVT Arthrography or joint lavage - < 18g needles (if ≥ 18 g needle follow Category 1 Procedure recommendations) FNA Breast Biopsy 	N/A	N/A	Do not withhold	Do not withhold	Do not withhold
---	-----	-----	--------------------	--------------------	--------------------

* For tube changes and dialysis interventions, labs within 3 months are acceptable unless interim change in therapy (eg, initiation of anticoagulation)

** These guidelines may be waived in certain circumstances on a case-by-case basis by the physician performing the procedure.

*** Medical Clearance -

If patient is taking anti-platelet agent (other than aspirin), they will need clearance from prescribing physician to stop.

- Clopidegrole (Plavix)
- ticagrelor (Brilinta)
- prasugrel (Effient)
- dipyridamole
- dipyridamole/aspirin (Aggrenox)
- ticlodipine (Ticlid)
- eptfibatide (Integrilin)

Any patient who is taking aspirin:

- <u>Prescribed by physician</u> for coronary stent or stroke will need clearance.
- Patient is taking for general cardiovascular risk reduction does not need clearance.



Medication	T 1/2	Category 1/2 procedures	Category 3 procedures	Elderly and Significant Renal Impairment (GFR < 50)
Clopidogrel (Plavix)	30 min (active metabolit e)	Withhold 5 days prior	Withhold 5 days prior	No renal adjustment
Aspirin	3 hrs	Do not withhold	Withhold 5 days prior	No renal adjustment
Ticagrelor (Brilinta)	9 hrs	Withhold 5 days prior	Withhold 5 days prior	No renal adjustment
Prasugrel (Effient)	7 hrs	Hold 7 days prior to procedure	Hold 7 days prior to procedure	No renal adjustment
Ibuprofen (Motrin/Advil)	2 hrs	Do not withhold	Withhold 24 hrs	N/A
Excedrin		Do not withhold	Withhold 5 days	N/A
Naproxen (Aleve)	12-17 hrs	Do not withhold	Withhold 2-3 days	N/A
Nabumetone (Relafen)	22 hrs	Do not withhold	Withhold 10 days	N/A
Warfarin (Coumadin)	20-60 hrs	If procedure in > 5 days: Hold 5 days prior and recheck INR If procedure in 1- 5 days: Hold and recheck INR If emergent: Hold and check INR, correct INR	If procedure in > 5 days: Hold 5 days prior and recheck INR If procedure in 1- 5 days: Hold and recheck INR If emergent: Hold and check INR, correct INR	No renal adjustment
Enoxaparin (Lovenox)	4.5 hr	Hold 1 day prior (may hold evening dose if BID regimen)	Hold 1 day prior (may hold evening dose if BID regimen)	No renal adjustment
Rivaroxaban (Xarelto)	5-9 hrs	Hold 24 hrs prior to procedure	Hold 36 hrs prior to procedure	Hold longer for renal impairment



				1
Apixiban (Eliquis)	8-11 hrs	Hold 24 hrs prior to procedure	Hold 36 hrs prior to procedure	No renal adjustment
Dabigatran (Pradaxa)	12-17 hrs	Hold 2-3 days if CrCl ≥ 50mL/min Hold 3-5 days if CrCl ≤ 50mL/min or for Lumbar puncture	Hold 2-3 days if CrCl ≥ 50mL/min Hold 3-5 days if CrCl ≤ 50mL/min or for Lumbar puncture	Hold longer for renal impairment
Un-fractionated Heparin (Heparin Drip)	1.5 hrs	Hold 4-6 hrs prior, check PTT	Hold 6 hrs prior, check PTT	No renal adjustment
Vitamin E		Do not withhold	Do not withhold	n/a
Avastin		Hold 14 days pre & post arterial procedures	Hold 14 days pre & post arterial procedures	n/a
Effient (Prasugrel)		Hold 7 days prior to procedure	Hold 7 days prior to procedure	n/a
Arixtra (Fondaparinux)		Hold 2-3 days if CrCl ≥ 50mL/min Hold 3-5 days if CrCl <u><</u> 50mL/min	Hold 2-3 days if CrCl ≥ 50mL/min Hold 3-5 days if CrCl <u><</u> 50mL/min	Renal adjustment as noted
Abciximab (Reopro)		Hold 1 day	Hold 1 day	
Aggrenox (ASA/DipyridamoleER)		Do not withhold	Hold 5 days prior to procedure	
Persantine (Dipyridamole)		Hold 5 days prior to procedure	Hold 5 days prior to procedure	
Oral Diabetic Medications		Hold day of procedure & 48 hours following contrast		

References:

 Indravadan J. Patel, MD et al. Consensus Guidelines for Periprocedural Management of Coagulation Status and Hemostasis Risk in Percutaneous Image-guided Interventions. J Vasc Interv Radiol 2012; 23:727–736



- 2. Cook, Brian W. MD. Anticoagulation Management. Seminars in Interventional Radiology Vol 27, Num 4 2010
- 3. Crockett, Matthew T. et al. The Novel Oral Anticoagulants: An Update for the Interventional Radiologist. American Journal of Roentgenology. 2012;199: W376-W379
- 4. Gonsalves, Wilson I. et al. The New Oral Anticoagulants in Clinical Practice. Mayo Clin Proc May 2013;88(5):495-511
- 5. Taslakian, Bedros et al. Patient Evaluation and Preparation in Vascular and Interventional Radiology: What Every Interventional Radiologist Should Know. Cardiovasc Intervent Radiol (2016) 39:489-499